A Randomized, Double-Blinded, Controlled Trial Evaluating Recombinant Human Platelet-Derived Growth Factor B (rhPDGF-BB)-Enhanced Wound Matrix in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision
Latest Information Update: 23 May 2025
At a glance
- Drugs GEM 21S (Primary)
- Indications Bone disorders
- Focus Therapeutic Use
Most Recent Events
- 15 May 2025 Status changed from not yet recruiting to recruiting.
- 31 Jan 2025 Planned End Date changed from 1 Feb 2026 to 1 May 2026.
- 31 Jan 2025 Planned primary completion date changed from 1 Feb 2026 to 1 May 2026.